Matrix Metalloproteinase-3 (MMP3) and MMP9 Genes and Risk of Myocardial Infarction, Ischemic Stroke, and Hemorrhagic Stroke

Overview

Journal Atherosclerosis

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2008 Mar 18

PMID 18342317

Citations 35

Authors

Robert C Kaplan

Nicholas L Smith

Stanley Zucker

Susan R Heckbert

Kenneth Rice

Bruce M Psaty

Affiliations

Soon will be listed here.

Abstract

Objective: We assessed the association of genetic variation in MMP3 and MMP9 with risk of myocardial infarction and stroke.

Methods: A case-control study was conducted among members of Group Health (GH), a large-integrated health care delivery system. Case subjects with incident non-fatal myocardial infarction (n=854), ischemic stroke (n=367), and hemorrhagic stroke (n=66) were identified and validated. A matched control group was selected from among GH members without myocardial infarction or stroke (n=2696). Haplotype-tagging sets of single-nucleotide polymorphisms (SNPs) in MMP3 and MMP9 were genotyped.

Results: MMP3 haplotype 2 was associated with reduced risk of myocardial infarction (adjusted odds ratio (OR) per copy=0.80, 95% confidence interval 0.66, 0.98) and increased risk of hemorrhagic stroke (OR=1.69, 95% confidence interval 1.05, 2.75). Results for MMP3 haplotype 2 and ischemic stroke resembled those for myocardial infarction but did not achieve statistical significance (OR=0.85, 95% confidence interval 0.64, 1.12). No individual SNP identified MMP3 haplotype 2, and none of the individual MMP3 SNPs were associated with myocardial infarction or stroke. MMP9 haplotypes or SNPs were not associated with myocardial infarction or stroke.

Conclusions: MMP3 haplotype may predict both cardiac events and stroke.

Citing Articles

Gene Polymorphism (rs3918242) Increases the Risk of Cardiovascular Disease in Type 2 Diabetes Patients.

Buraczynska M, Wrzos S, Zaluska W J Clin Med. 2023; 12(22).

PMID: 38002605 PMC: 10672737. DOI: 10.3390/jcm12226990.

Association of MMP3, MMP14, and MMP25 gene polymorphisms with cerebral stroke risk: a case-control study.

Yin Y, Zhang Y, Zhang X, Zhang Q, Wang J, Yang T BMC Med Genomics. 2023; 16(1):297.

PMID: 37986083 PMC: 10659043. DOI: 10.1186/s12920-023-01734-1.

Matrix metalloproteinases and their gene polymorphism in young ST-segment elevation myocardial infarction.

Basia D, Gupta M, Kunal S, Muheeb G, Girish M, Bansal A Indian Heart J. 2022; 74(6):519-523.

PMID: 36370803 PMC: 9773251. DOI: 10.1016/j.ihj.2022.11.001.

The roles of MMP8/MMP10 polymorphisms in ischemic stroke susceptibility.

Zhao Y, Zhang Q, Zhang X, Zhang Y, Lu Y, Ma X Brain Behav. 2022; 12(12):e2797.

PMID: 36282475 PMC: 9759140. DOI: 10.1002/brb3.2797.

Matrix Metalloproteinase-9 Gene Polymorphism and Its Methylation in Stroke Patients.

Choudhari O, Rani A, Kampani G, Kaur C, Sengupta A Malays J Med Sci. 2022; 28(6):32-41.

PMID: 35002488 PMC: 8715877. DOI: 10.21315/mjms2021.28.6.4.

References

Galis Z, Sukhova G, Lark M, Libby P . Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94(6):2493-503. PMC: 330083. DOI: 10.1172/JCI117619. View

Liu P, Li Y, Chan S, Lin L, Wu H, Shi G . Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am J Cardiol. 2006; 98(8):1012-7. DOI: 10.1016/j.amjcard.2006.05.017. View

Rosenberg G . Matrix metalloproteinases in neuroinflammation. Glia. 2002; 39(3):279-91. DOI: 10.1002/glia.10108. View

Zucker S, Hymowitz M, Conner C, Zarrabi H, Hurewitz A, Matrisian L . Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci. 1999; 878:212-27. DOI: 10.1111/j.1749-6632.1999.tb07687.x. View

Bini A, Itoh Y, Kudryk B, Nagase H . Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond. Biochemistry. 1996; 35(40):13056-63. DOI: 10.1021/bi960730c. View

Smith N, Hindorff L, Heckbert S, Lemaitre R, Marciante K, Rice K . Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA. 2007; 297(5):489-98. DOI: 10.1001/jama.297.5.489. View

Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen H . Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost. 2007; 5(8):1732-9. DOI: 10.1111/j.1538-7836.2007.02628.x. View

Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries S, Henney A . Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996; 271(22):13055-60. DOI: 10.1074/jbc.271.22.13055. View

Lamblin N, Bauters C, Hermant X, Lablanche J, Helbecque N, Amouyel P . Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol. 2002; 40(1):43-8. DOI: 10.1016/s0735-1097(02)01909-5. View

10.

Rosenberg G, Cunningham L, Wallace J, Alexander S, Estrada E, Grossetete M . Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 2001; 893(1-2):104-12. DOI: 10.1016/s0006-8993(00)03294-7. View

11.

Medley T, Cole T, Dart A, Gatzka C, Kingwell B . Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol. 2004; 24(8):1479-84. DOI: 10.1161/01.ATV.0000135656.49158.95. View

12.

Zhou X, Huang J, Chen J, Su S, Chen R, Gu D . Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thromb Haemost. 2004; 92(4):867-73. DOI: 10.1160/TH04-03-0192. View

13.

Beyzade S, Zhang S, Wong Y, Day I, Eriksson P, Ye S . Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol. 2003; 41(12):2130-7. DOI: 10.1016/s0735-1097(03)00482-0. View

14.

Lijnen H, Arza B, Van Hoef B, Collen D, Declerck P . Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). J Biol Chem. 2000; 275(48):37645-50. DOI: 10.1074/jbc.M006475200. View

15.

Kim J, Park H, Kwon J, Im E, Choi D, Jang Y . The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J. 2002; 43(4):473-81. DOI: 10.3349/ymj.2002.43.4.473. View

16.

Stephens M, Smith N, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68(4):978-89. PMC: 1275651. DOI: 10.1086/319501. View

17.

Yoon S, Tromp G, Vongpunsawad S, Ronkainen A, Juvonen T, Kuivaniemi H . Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun. 1999; 265(2):563-8. DOI: 10.1006/bbrc.1999.1721. View

18.

Heckbert S, Li G, Cummings S, Smith N, Psaty B . Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008; 168(8):826-31. DOI: 10.1001/archinte.168.8.826. View

19.

French B, Lumley T, Monks S, Rice K, Hindorff L, Reiner A . Simple estimates of haplotype relative risks in case-control data. Genet Epidemiol. 2006; 30(6):485-94. DOI: 10.1002/gepi.20161. View

20.

Flex A, Gaetani E, Papaleo P, Straface G, Proia A, Pecorini G . Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke. 2004; 35(10):2270-5. DOI: 10.1161/01.STR.0000140740.19421.fe. View